A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer
Authors:
- Michael V. SeidenMSMichael V. Seiden
- Alan N. GordonAGAlan N. Gordon
- Diane C. BodurkaDBDiane C. Bodurka
- Ursula A. MatulonisUMUrsula A. Matulonis
- Richard T. PensonRPRichard T. Penson
- Eddie ReedEREddie Reed
- Dave S. AlbertsDADave S. Alberts
- Garry WeemsGWGarry Weems
- Michael CullenMCMichael Cullen
- William P. McGuireWMWilliam P. McGuire
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 101 (1) , 55-61
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group studyGynecologic Oncology, 2005
- Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancerGynecologic Oncology, 2004
- Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyGynecologic Oncology, 2004
- Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer PatientsOncology, 2004
- Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecologic Oncology, 2004
- Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancerGynecologic Oncology, 2003
- Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II studyGynecologic Oncology, 2003
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)Biochemical Pharmacology, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997